EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications

Olivia Vandekerckhove iD, Kristof Cuppens iD, Karin Pat, Bert Du Pont, Guy Froyen iD, Brigitte Maes

Cancers · 10.05.2023 · 15 (10) · 2702

DOI: 10.3390/cancers15102702 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.05.2023. Verfasst von Olivia Vandekerckhove und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department Pulmonology and Thoracic Oncology, Jessa Hospital, 3500 Hasselt, Belgium. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer death worldwide, with the majority of cases diagnosed in an advanced stage. Early-stage disease non-small cell lung cancer (NSCLC) has a better outcome, nevertheless the 5-year survival rates drop from 60% for stage IIA to 36% for stage IIIA disease. Early detection and optimized perioperative systemic treatment are frontrunner strategies to reduce this burden. The rapid advancements in molecular diagnostics as well as the growing availability of targeted therapies call for the most efficient detection of actionable biomarkers. Liquid biopsies have already proven their added value in the management of advanced NSCLC but can also optimize patient care in early-stage NSCLC. In addition to having known diagnostic benefits of speed, accessibility, and enhanced biomarker detection compared to tissue biopsy, liquid biopsy could be implemented for screening, diagnostic, and prognostic purposes. Furthermore, liquid biopsy can optimize therapeutic management by overcoming the issue of tumor heterogeneity, monitoring tumor burden, and detecting minimal residual disease (MRD), i.e., the presence of tumor-specific ctDNA, post-operatively. The latter is strongly prognostic and is likely to become a guidance in the postsurgical management. In this review, we present the current evidence on the clinical utility of liquid biopsy in early-stage lung cancer, discuss a selection of key trials, and suggest future applications.

Schlagwörter

Stichwörter der Autor:innen

circulating tumor DNAearly stageliquid biopsyminimal residual diseasemolecular diagnosticsnon-small cell lung cancerreviewscreeningtargeted therapy

Autor:innen und Institutionen

  • Department Pulmonology and Thoracic Oncology, Jessa Hospital, 3500 Hasselt, Belgium.
  • Department Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam and Leiden University Medical Center, 2333 Leiden, The Netherlands.
  • Faculty of Medicine and Life Sciences-LCRC, Hasselt University, 3590 Diepenbeek, Belgium.
  • Department Thoracic and Vascular Surgery, Jessa Hospital, 3500 Hasselt, Belgium.
  • Laboratory for Molecular Diagnostics, Department Laboratory Medicine, Jessa Hospital, 3500 Hasselt, Belgium.

ORCID-Profile: Olivia Vandekerckhove, Kristof Cuppens, Guy Froyen

Zitieren

APA

Vandekerckhove, O., Cuppens, K., Pat, K., Du Pont, B., Froyen, G., & Maes, B. (2023). Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications. Cancers, 15(10), 2702. https://doi.org/10.3390/cancers15102702

Vancouver

Vandekerckhove O, Cuppens K, Pat K, Du Pont B, Froyen G, Maes B. Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications. Cancers. 2023;15(10):2702. doi:10.3390/cancers15102702

BibTeX
@article{Vandekerckhove2023,
  author = {Vandekerckhove, Olivia and Cuppens, Kristof and Pat, Karin and Du Pont, Bert and Froyen, Guy and Maes, Brigitte},
  title = {Liquid Biopsy in Early-Stage Lung Cancer: Current and Future Clinical Applications},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {10},
  pages = {2702},
  doi = {10.3390/cancers15102702}
}
Kostenlos starten →